Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Provides a source of amino acids and dextrose for parenteral nutrition; amino acids support protein synthesis, dextrose provides calories. Electrolytes maintain fluid and electrolyte balance.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients requiring central venous administration when oral or enteral nutrition is not possible or insufficient,Metabolic support in catabolic states,Off-label: Supplementation in patients with protein-calorie malnutrition
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion. Dose is based on nutritional requirements and metabolic tolerance. Typical adult dose: 1-2 L per day (providing 4.25% amino acids and 10% dextrose) at a rate not exceeding 4 mg/kg/min of dextrose. Administer via central line or peripheral vein if osmolarity permits.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Amino acids: 0.5-1 hour (rapid clearance from plasma). Dextrose: effectively infinite as continuous infusion maintains steady state. Electrolytes: dependent on renal function and tubular handling.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids are primarily metabolized in the liver via transamination and deamination; dextrose undergoes glycolysis and oxidation. Electrolytes are not metabolized but are excreted or retained as needed.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Amino acids: primarily deaminated in liver, urea excreted renally. Dextrose: metabolized to CO2 and water, with excess excreted renally as glucose. Electrolytes: renal excretion. No significant biliary/fecal elimination for components.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids: minimal (<10%, primarily albumin). Dextrose: not protein-bound. Electrolytes: variable (calcium ~50% bound to albumin; magnesium ~30% bound; others minimal).
Minimal (<10%) for most amino acids; not significantly protein-bound.
Amino acids: 0.1-0.3 L/kg (primarily extracellular fluid). Dextrose: 0.2-0.3 L/kg (total body water). Electrolytes: calcium 0.4-0.5 L/kg; magnesium 0.3-0.5 L/kg; others distributed in extracellular fluid.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous: 100%.
Intravenous: 100%.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) unless patient is receiving renal replacement therapy. For patients with e GFR 30-60 m L/min/1.73 m², reduce total protein/amino acid intake to 0.6-0.8 g/kg/day and monitor electrolytes, particularly potassium, phosphate, and magnesium. For e GFR > 60, no adjustment typically needed but monitor fluid/electrolyte balance.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Use with caution in hepatic impairment. For Child-Pugh Class A (mild): standard dosing with monitoring of ammonia levels. Child-Pugh B (moderate): reduce amino acid dose by 50% and consider branched-chain amino acid enriched solutions; monitor for hepatic encephalopathy. Child-Pugh C (severe): avoid use unless essential; if used, start at 25% of standard dose with frequent ammonia monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Weight-based dosing: initial infusion at 0.5-1 g/kg/day of amino acids, increase by 0.5 g/kg/day to target 2-3 g/kg/day for infants and 1-2 g/kg/day for older children. Dextrose: start at 4-8 mg/kg/min, titrate based on glucose tolerance. Maximum dextrose infusion rate: 12 mg/kg/min for neonates, 14 mg/kg/min for infants. Adjust volume to meet fluid requirements.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Start at lower end of dosing range (e.g., initial rate 1 m L/kg/hour). Monitor renal function and adjust protein content to e GFR. Maximum dextrose rate: 2-3 mg/kg/min in patients >70 years to avoid hyperglycemia. Limit total fluid volume to 20-30 m L/kg/day unless fluid overload contraindicates.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Solutions containing aluminum may be toxic; aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment. Premature neonates are at increased risk because of immature renal function and aluminum accumulation.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Risk of infection or sepsis due to catheter-related infections,Metabolic complications including hyperglycemia, hypoglycemia, hyperosmolar syndrome, electrolyte imbalances, and acid-base disturbances,Hepatic and renal function monitoring required,Aluminum toxicity risk, especially in premature neonates and renal impairment,Not for peripheral administration due to high osmolarity (>900 m Osm/L)
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Unstable hyperglycemia or severe insulin resistance,Severe electrolyte disturbances without correction,Hepatic coma or severe hepatic impairment,Severe renal impairment (unless dialysis is available),Inborn errors of amino acid metabolism,Pulmonary edema or heart failure (if fluid overload is a concern)
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
Food interactions are not clinically relevant for intravenous administration. However, oral intake may be restricted due to the patient's condition (e.g., NPO status).
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
CLINIMIX E 4.25/10 is a parenteral nutrition solution containing amino acids, dextrose, electrolytes, and calcium. No specific teratogenic risks are well-documented for the combination. Dextrose at high doses may cause fetal hyperglycemia and macrosomia if maternal glucose control is impaired. Calcium is essential for fetal development; excess could theoretically cause hypercalcemia-related effects. Overall, no specific malformation pattern is established. Trimester-specific risks are not defined; use is justified only if maternal benefits outweigh potential fetal risks.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
No specific data on CLINIMIX E excretion in breast milk. Components (amino acids, dextrose, electrolytes) are normal blood constituents and likely excreted at low concentrations. M/P ratio not available. Generally compatible with breastfeeding if maternal clinical status permits.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy increases plasma volume and renal blood flow, potentially increasing clearance of amino acids and electrolytes. Glucose metabolism may be altered due to insulin resistance. Dose adjustments: dextrose infusion may need to be tailored to avoid maternal hyperglycemia (target glucose <7.8 mmol/L). Electrolyte requirements may increase for fetal growth (calcium, phosphate). No specific weight-based formulas established; individualize based on maternal weight, trimester, and metabolic monitoring.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
Monitor serum electrolytes, glucose, and acid-base status frequently during infusion. Use inline filter (1.2 micron) due to calcium-phosphate precipitation risk. Avoid simultaneous blood transfusions through same line. Do not administer if lipid emulsion is needed concurrently. Adjust infusion rate based on tolerance and metabolic status.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This solution provides nutrition, fluids, and electrolytes through a vein.,Report any signs of infection at IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience headache, nausea, or shortness of breath.,Do not stop the infusion suddenly without consulting your doctor.,This product contains calcium and should not be mixed with certain other IV solutions.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Provides a source of amino acids and dextrose for parenteral nutrition; amino acids support protein synthesis, dextrose provides calories. Electrolytes maintain fluid and electrolyte balance.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion. Dose is based on nutritional requirements and metabolic tolerance. Typical adult dose: 1-2 L per day (providing 4.25% amino acids and 10% dextrose) at a rate not exceeding 4 mg/kg/min of dextrose. Administer via central line or peripheral vein if osmolarity permits.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/10 is a parenteral nutrition solution containing amino acids, dextrose, electrolytes, and calcium. No specific teratogenic risks are well-documented for the combina. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.